AUM Biosciences, a Singapore-based biotech company, raised USD$27M in Series A funding.
The round was led by Everlife with participation from SPRIM Global Investment.
The company intends to use the funds to accelerate pipeline development and expansion and business growth.
Led by Vishal Doshi, CEO, and Harish Dave, CMO, AUM Biosciences is a clinical stage biotech company focused on discovering and developing novel targeted oncology therapies, particularly for cancers.
Through its strategic collaborations with academic institutions, pharmaceutical and biotech companies globally, AUM is now leading an ecosystem of multi-modality line up of small molecule targeted therapies, including in-house research programs. AUM plans to use the proceeds to advance the clinical development of its portfolio with immediate initiation of two-Phase II programs for MNK and TRK inhibitors.
Earlier this year, AUM had entered into a strategic collaboration agreement with Handok Inc and CMG Pharmaceutical Co. Ltd. Additionally, AUM Biosciences and Newsoara Biopharma also announced a 5-year transformational strategic partnership in 2020 to co-develop and co-discover next-generation cancer therapeutics (enterprise value of up to USD 135M).
FinSMEs
13/10/2021